Rappaport, Stephen A., Marcus, Ronald N., Manos, George, McQuade, Robert D., Oren, Dan A.

Objectives: To evaluate the tolerability of intramuscular (IM) aripiprazole in patients with agitation associated with dementia.; Design: A 24-hour, double-blind, placebo-controlled, randomized study.; Setting: Sixteen healthcare facilities in the United States.; Participants: A total of 129 patients with acute agitation associated with Alzheimer’s, vascular or mixed dementia in healthcare facilities.; Intervention: Patients were randomized to […]

Huntington Study Group Reach2HD Investigators,

Background: PBT2 is a metal protein-attenuating compound that might reduce metal-induced aggregation of mutant huntingtin and has prolonged survival in a mouse model of Huntington’s disease. We aimed to assess the safety, tolerability, and efficacy of PBT2 in patients with Huntington’s disease. Methods: In this 26-week, randomised, double-blind, placebo-controlled trial, adults (≥ 25 years old) […]

Finger, E. C., MacKinley, J., Blair, M., Oliver, L. D., Jesso, S., Tartaglia, M. C., Borrie, M., Wells, J., Dziobek, I., Pasternak, S., Mitchell, D. G. V., Rankin, K., Kertesz, A., Boxer, A.

Objective: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). Methods: We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for […]